ESC Premium Access

SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes


About the speaker

Doctor Caroline Holm Noergaard

Aalborg University Hospital, Aalborg (Denmark)
0 follower

4 more presentations in this session

State of the Art - SGLT2 inhibitors in cardiovascular disease

Speaker: Professor M. Sabatine (Boston, US)


Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Speaker: Doctor T. Zelniker (Vienna, AT)


Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

Speaker: Doctor J. Udell (Toronto, CA)


Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists

Speaker: Professor N. Sattar (Glasgow, GB)


Access the full session

New frontiers: SGLT2 inhibitors in cardiorenal disease

Speakers: Doctor C. Noergaard, Professor M. Sabatine, Doctor T. Zelniker, Doctor J. Udell, Professor N. Sattar

About the event



31 August - 4 September 2019

Sessions Presentations

Related content

ESC Premium Access

Mechanical support devices in STEMI and shock: when and in whom?

30 August 2021

ESC Premium Access

External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy

29 August 2021

ESC Premium Access

Prognostic value of fractional flow reserve using computed tomography for predicting major adverse cardiac events and mortality in kidney transplant candidates

29 August 2021

This platform is supported by

logo Novo Nordisk